[go: up one dir, main page]

WO1991018618A3 - Compositions immunotherapeutiques de traitement et de prevention d'infections dues au sida, au para-sida et au vih - Google Patents

Compositions immunotherapeutiques de traitement et de prevention d'infections dues au sida, au para-sida et au vih Download PDF

Info

Publication number
WO1991018618A3
WO1991018618A3 PCT/US1991/003460 US9103460W WO9118618A3 WO 1991018618 A3 WO1991018618 A3 WO 1991018618A3 US 9103460 W US9103460 W US 9103460W WO 9118618 A3 WO9118618 A3 WO 9118618A3
Authority
WO
WIPO (PCT)
Prior art keywords
human
prophylactic
treating
useful
immunotherapeutic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1991/003460
Other languages
English (en)
Other versions
WO1991018618A2 (fr
Inventor
Richard A Fisher
Catherine Hession
Linda C Burkly
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Original Assignee
Biogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Inc filed Critical Biogen Inc
Publication of WO1991018618A2 publication Critical patent/WO1991018618A2/fr
Publication of WO1991018618A3 publication Critical patent/WO1991018618A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/702—Specific hybridization probes for retroviruses
    • C12Q1/703—Viruses associated with AIDS
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70514—CD4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/0337—Animal models for infectious diseases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Environmental Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • AIDS & HIV (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Animal Husbandry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compositions immunothérapeutiques, prophylactiques et diagnostiques utilisées dans le traitement ou la prévention de maladies chez l'homme provoquées par des agents infectieux dont les cibles primaires sont les lymphocytes T4+, comprenant les infections du syndrome d'immunodéficience acquise, du complexe apparenté au SIDA et du virus d'immunodéficience humaine. L'invention concerne également des séquences d'ADN codant des variantes d'acide aminé ainsi que des dérivés de CD4 humaine, ou des fragments de ceux-ci, apparaissant dans des anticorps humains se liant à la gp120 du VIH. Lesdites séquences d'ADN sont utiles dans les compositions immunothérapeutiques, prophylactiques et diagnostiques de l'invention. De plus, l'invention concerne un nouveau procédé de triage permettant de sélectionner des variantes d'acide aminé ainsi que des dérivés de CD4 humaine apparaissant dans des anticorps humains se liant à la gp120 du VIH, la CD4 humaine ou les deux, utilisés comme agents thérapeutiques, prophylactiques et diagnostiques contre des maladies provoquées par des agents infectieux dont les cibles primaires sont les lymphocytes T4+, comprenant les infections dues au syndrome d'immunodéficience acquise, au complexe apparenté au SIDA et au virus d'immunodéficience humaine.
PCT/US1991/003460 1990-05-25 1991-05-23 Compositions immunotherapeutiques de traitement et de prevention d'infections dues au sida, au para-sida et au vih Ceased WO1991018618A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52918690A 1990-05-25 1990-05-25
US529,186 1990-05-25

Publications (2)

Publication Number Publication Date
WO1991018618A2 WO1991018618A2 (fr) 1991-12-12
WO1991018618A3 true WO1991018618A3 (fr) 1992-04-16

Family

ID=24108870

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/003460 Ceased WO1991018618A2 (fr) 1990-05-25 1991-05-23 Compositions immunotherapeutiques de traitement et de prevention d'infections dues au sida, au para-sida et au vih

Country Status (6)

Country Link
EP (1) EP0491888A4 (fr)
JP (1) JPH05502166A (fr)
AU (1) AU7976791A (fr)
CA (1) CA2062758A1 (fr)
OA (1) OA09648A (fr)
WO (1) WO1991018618A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2692435A1 (fr) * 1992-06-19 1993-12-24 Transgene Sa Lapin transgénique sensible au HIV, son usage à titre de modèle animal et son procédé d'obtention.
FR2696188A1 (fr) * 1992-09-25 1994-04-01 Curie Paris Vi Univ Pierre Mar Molécule CD4 de chat, séquence nucléique codant pour cette molécule et leurs applications.
AU2003225612A1 (en) * 2002-02-27 2003-09-09 Prodigene, Inc. Expression of hiv-related proteins in plants
US10150970B2 (en) 2011-07-27 2018-12-11 Applied Biotechnology Institute, Inc. Methods to increase antigenicity of membrane-bound polypeptides produced in plants

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001940A1 (fr) * 1987-09-04 1989-03-09 Biogen, Inc. Sequences d'adn, molecules d'adn recombinant et procedes de production de proteines t4 solubles
EP0330227A2 (fr) * 1988-02-24 1989-08-30 The Trustees Of Columbia University In The City Of New York Dérivés de T-4 solubles

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989001940A1 (fr) * 1987-09-04 1989-03-09 Biogen, Inc. Sequences d'adn, molecules d'adn recombinant et procedes de production de proteines t4 solubles
EP0330227A2 (fr) * 1988-02-24 1989-08-30 The Trustees Of Columbia University In The City Of New York Dérivés de T-4 solubles

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CELL. Vol. 60, 9 March 1990, Cambridge, NA US pages 747 - 754; CAMERINI, D. et al.: 'A CD4 domain important for HIV-mediated syncytium formation lies outside the virus binding site'. see the whole document. *
MOLECULAR BIOLOGY AND MEDECINE vol. 6, September 1989, ACADEMIC PRESS pages 255 - 261; YU, S. et al.: 'Functional human CD4 protein produced in milk in transgenic mice' see the whole document. *
SCIENCE. Vol. 240, 10 June 1988, Lancaster, PA US pages 1468 - 1474; JAENISH, R.: 'Transgenic Animals' see the whole document. *
SCIENTIFIC AMERICAN October 1988, pages 88 - 97; YARKOAN, R. et al: 'Aids Therapies' see the whole document. *
THE JOURNAL OF EXPERIMENTAL MEDECINE Vol. 170, Octobet 1989, THE ROCKEFELLER UNIV. PRESS pages 1319 - 1334; SATENTAU, Q.J. et al.: 'Structural analysis of the human immunodeficiency virus-binding doamin of CD4'. see the whole document. *

Also Published As

Publication number Publication date
JPH05502166A (ja) 1993-04-22
WO1991018618A2 (fr) 1991-12-12
EP0491888A4 (en) 1992-09-02
AU7976791A (en) 1991-12-31
EP0491888A1 (fr) 1992-07-01
OA09648A (en) 1993-05-15
CA2062758A1 (fr) 1991-11-26

Similar Documents

Publication Publication Date Title
CA2073031A1 (fr) Homologues d'anticorps anti-cd4 utilises a titre prophylactique et dans le traitement du sida, du para-sida et des infections par le vih
CA2082948A1 (fr) Peptides et anticorps immunogenes et leurs utilisations pour la fixation au recepteur des cd4
ES2013346A6 (es) Metodos para producir secuencias y moleculas de adn recombinante, asi como proteinas t4 solubles.
MY136081A (en) Modified hiv - 1gag p17 peptide and immunogenic composition
CA2363947A1 (fr) Peptides, antigenes du vih, compositions de vaccins afferentes, trousse de dosage immunologique et methode de detection d'anticorps induits par le vih
DE3588254D1 (de) Gag-Antigen und dessen Verwendung zum Nachweis von LAV-Infektion, sowie in immunogenen Zusammensetzungen
AU8083594A (en) Synthetic human neutralizing monoclonal antibodies to human immunodeficiency virus
EP0328403A3 (fr) Peptides synthétiques relatifs à la protéine HIV-GP120-env. et leur application
CA2192512A1 (fr) Anticorps monoclonal nmo3; methodes d'utilisation
KR930702509A (ko) 사람 면역결핍 바이러스(hiv)면역치료제
WO2002020555A3 (fr) Peptides regulateurs et auxiliaires de vih, antigenes, compositions de vaccin, trousses de dosage immunologique et procede de detection d'anticorps induits par vih
EP0491888A4 (en) Immunotherapeutic compositions for treating and preventing aids, arc and hiv infection
CA2057612A1 (fr) Peptides selectionnes de l'antigene specifique au groupe (gag) du virus de l'immunodeficience humaine (vih), sa preparation et son utilisation
CA2160696A1 (fr) Peptides utiles pour la vaccination et l'induction d'anticorps neutralisateurs contre le virus de l'immunodefience humaine
WO2003089000A3 (fr) Composition anti-vih, comprenant un polyanion et un agent agissant sur gp120 de acon equivalent au cd4
KR100871455B1 (ko) Ｈｉｖ 바이러스에 대한 천연 항체
EP1104770A3 (fr) Compositions et procédés pour déceler et traiter le syndrome immunodéficitaire acquis
AU651113B2 (en) HIV GP120 monoclonal antibodies
WO2002034909A3 (fr) Chimere de fragments de proteines synthetisee et ses methodes d'utilisation
EP0293792A3 (fr) Protéines encodées par GAG du virus d'immunodéficience humaine
EP0218431A3 (en) Novel polypeptides, dnas that code for the same and method of preparing said polypeptides and dnas
FR2646607B1 (fr) Anticorps monoclonaux anti-b2 microglobuline
AU627540B2 (en) Drug for the treatment or prevention by passive immunization, of the hiv-infection and process for preparation thereof
CA2046016A1 (fr) Anticorps monoclonal du vih
WO1991009872A3 (fr) Polypeptides selectivement reactifs avec des anticorps contre le virus d'immunodeficience humaine et vaccins comprenant les polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2062758

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991910648

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE BF BJ CF CG CH CI CM DE DK ES FR GA GB GR IT LU ML MR NL SE SN TD TG

WWP Wipo information: published in national office

Ref document number: 1991910648

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991910648

Country of ref document: EP